Roth starts Intellipharmaceutics at buy

Roth Capital Partners has initiated coverage of Intellipharmaceutics (NASDAQ:IPCI; TSX:I) with a “buy” rating and 12-month price target of $5.25, saying the emerging generics company could launch four new products in the coming 12-to-18 months. “We believe that this momentum could unlock value for this under covered stock,” writes analyst Scott Henry. The stock closed [...]

Intellipharmaceutics and Par amend Focalin XR pact

Intellipharmaceutics International (NADAQ:IPCI; TSX:I) and Par Pharmaceutical have added the development and commercialization of additional strengths of generic Focalin XR for the U.S. market to their existing agreement, which applied to the development and commercialization of the 5, 10, 15 and 20 mg strengths of generic Focalin XR. Five strengths (5, 10, 15, 20 and 30 mg) [...]

Intellipharmaceutics CEO moulded at Biovail U

Fifteen years ago, Dr. Isa Odidi performed magic as CSO of Biovail (NYSE:BVF; TSX:BVF), developing several blockbuster generics, including hard-to-manufacture copies of Bayer’s Adalat CC, Pfizer’s Procardia XL and Novartis’ Voltaren XR. “We have the same style here at Intellipharmaceutics (NASDAQ:IPCI; TSX:I) as we had at Biovail,” Dr. Odidi says in an exclusive interview with [...]

Intellipharmaceutics advances abuse-deterrent oxycodone

Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) has taken delivery of and fully qualified its primary manufacturing equipment for the manufacture of oxycodone CR, an abuse-deterrent formulation of controlled-release oxycodone hydrochloride. The company also said it has begun making clinical batches of the drug for Phase 1 studies and to establish a clinical program in cooperation with the [...]

FDA accepts Intellipharmaceutics ANDA

The FDA has accepted an abbreviated new drug application from Intellipharmaceutics International (NASDAQ:IPCI; TSX:I) for a generic version of the antidepressant Effexor XR. “This product was entirely developed and filed using our in-house laboratory, manufacturing and regulatory resources,” CEO Dr. Isa Odidi said in a statement.  “The acceptance of this filing also fulfills one of [...]

Intellipharmaceutics in patent settlement for generic Focalin XR

Intellipharmaceutics International (TSX:I; NASDAQ:IPCI) announced patent settlements over a generic version of the attention deficit hyperactivity disorder drug Focalin XR in the U.S. In a statement, the company said Novartis Pharmaceuticals (NYSE:NVS) and Celgene (NASDAQ:CELQ) have settled their patent suit in the U.S. District Court for the District of New Jersey.  Also, Elan Pharma International [...]